Novel taxane formulations in the treatment of breast cancer: A thought leader discussion and consensus roundtable

Clinical Breast Cancer

Volumn 8, Issue 1, 2008, Pages 33-37

  Gralow, Julie ^a   Rugo, Hope ^b   Gradishar, William ^c   O'Shaughnessy, Joyce A ^d   Jahanzeb, Mohammed ^e   Perez, Edith ^f   Tripathy, Debu ^g,h  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d TEXAS ONCOLOGY   (United States)

^e UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Albumin bound paclitaxel; Capecitabine; Docetaxel; Gemcitabine; Metastatic disease

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADD ON THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG FORMULATION; FATIGUE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MONOTHERAPY; NEUTROPENIA; PERIPHERAL NEUROPATHY;

EID: 40449109379     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.046     Document Type: Conference Paper

References (35)

1. N Desai V Trieu Z Yao Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, nab paclitaxel, ABI-007, compared with cremophorbased paclitaxel Clin Cancer Res 12 2006 1317 1324
2. WJ Gradishar S Tjulandin N Davidson Phase III trial of nanoparticle nab paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803
3. JL Blum MA Savin G Edelman Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes Clin Breast Cancer 7 2007 850 856
4. WJ Gradishar D Krasnojon S Cheporov A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC) Breast Cancer Res Treat 100 suppl 1 2006 s21 (Abstract 46).
5. Abraxane™ [package insert] January 7, 2005 Abraxis Schaumberg, IL Available at: http://www.fda.gov/cder/foi/label/2005/021660lbl. pdf
6. S Verma M Clemons First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy Oncologist 12 2007 785 797
7. EL Mayer HJ Burstein Chemotherapy for metastatic breast cancer Hematol Oncol Clin N Am 21 2007 257 272
8. WB Ershler Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer Oncologist 11 2006 325 335
9. J O'Shaughnessy D Miles S Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2002 2812 2823
10. KS Albain S Nag G Calderillo-Ruiz Global phase III study of gemcitabine plus paclitaxel vs. paclitaxel as frontline therapy for metastatic breast cancer: first report of overall survival Proc Am Soc Clin Oncol 23 2004 5 (Abstract 510).
11. KD Miller M Wang G Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New Engl J Med 357 2007 2666 2676
12. C Fan DS Oh L Wessels Concordance among gene-expressionbased predictors for breast cancer N Engl J Med 355 2006 560 569
13. JE Garber A Richardson LN Harris Neo-adjuvant cisplatin in “triple-negative” breast cancer Breast Cancer Res Treat 100 suppl 1 2006 s149 (Abstract 3074).
14. Trieu V, Hwang J, Zaidi S, et al. SPARC overexpression enhances sensitivity to nab-paclitaxel in vivo. Presented at: 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract 3480.
15. Trieu V, Damascelli B, Soon-Shiong P, et al. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle nab paclitaxel (nab-paclitaxel, ABI-007, Abraxane). Presented at: 97th Annual Meeting of the American Association for Cancer Research; April 1-5, 2006; Washington, DC. Abstract 4477.
16. BR Daniel H Doss V Gian Biweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathologic responses: results of a multicenter phase II trial J Clin Oncol 25 18 suppl 2007 599s (Abstract 11060).
17. V Valero SE Jones DD Von Hoff A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 1998 3362 3368
18. SE Jones J Erban B Overmoyer Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 2005 5542 5551
19. AD Seidman D Berry C Cirrincione Randomized trial of weekly versus every 3 weekly paclitaxel in metastatic breast cancer with randomization for trastuzumab or not in HER2-non-overexpressors: CALGB 9840 J Clin Oncol 2008 In press.
20. MW Verrill J Lee DA Cameron Anglo-Celtic IV: rirst results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer J Clin Oncol 25 18 suppl 2007 33s (Abstract LBA1005).
21. J Tabernero MA Climent A Lluch A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann Oncol 15 2004 1358 1365
22. PH Willemse L Munck GJ Creemers A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer Breast Cancer Res Treat 106 suppl 1 2007 s70 (Abstract 1083).
23. EP Winer DA Berry S Woolf Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342 J Clin Oncol 22 2004 2061 2068
24. A Gennari P Conte R Rosso Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies Cancer 104 2005 1742 1750
25. AK Conlin AD Seidman ME Moynehan Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer J Clin Oncol 25 18 suppl 2007 58s (Abstract 1104).
26. CE Geyer J Forster D Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published erratum in N Engl J Med 2007; 356:1487] N Engl J Med 355 2006 2733 2743
27. G von Minckwitz P Vogel M Schmidt Trastuzumab treatment beyond progression in patients with HER2-positive metastatic breast cancer - the TBP study (BGB 26/BIG 3-05) Breast Cancer Res Treat 106 suppl 1 2007 s185 (Abstract 4056).
28. AD Seidman M Danso A Bach Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer J Clin Oncol 24 18 suppl 2006 580s (Abstract 10650).
29. Mehta RS, Kong K, Schubbert T. Weekly nab-paclitaxel (nab-T) ± carboplatin (C) ± bevacizumab (B) or ± trastuzumab (H): Clinical response in patients with advanced breast cancer. Presented at: the American Society of Clinical Oncology 2007 Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract 162.
30. N Bogdanova S Tjulandin N Ognerubov A phase 2b multicenter evaluation of the safety and efficacy of Tocosol® paclitaxel (TOC-P) as initial treatment of patients with metastatic breast cancer (MBC) Breast Cancer Res Treat 94 suppl 1 2005 s62 (Abstract 1070).
31. Sonus Pharmaceuticals, Inc. [press release] Available at: http://www.biospace.com/news_story.aspx?NewsentityId=70726
32. J Cortes J Baselga Targeting the microtubules in breast cancer beyond taxanes: the epothilones Oncologist 12 2007 271 280
33. JL Blum B Pruitt CJ Fabian Phase II study of eribulin mesylate (E7389) halichondrin B analog in patients with refractory breast cancer J Clin Oncol 25 18 suppl 2007 40s (Abstract 1034).
34. ES Thomas HL Gomez RK Li Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 2007 5210 5217
35. EA Perez G Lerzo X Pivot Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 2007 3407 3414